Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: PF-04805712

Study type: Interventional

Funder types: Industry

Identifiers

NCT00991016

B1411001

Details and patient eligibility

About

To assess the safety and tolerability of escalating single and multiple doses of the compound in healthy volunteers

Enrollment: 61 patients

Sex: All

Ages: 21 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males and females of non-childbearing potential.

Exclusion criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

61 participants in 1 patient group

PF-04805712

Experimental group

Treatment:

Drug: PF-04805712